SMT's Supraflex Cruz Shows Consistent and Robust Clinical Outcomes Across Key Global Studies Presented at TCT 2025
Oct 29, 2025
Mumbai (Maharashtra) [India], October 29: Sahajanand Medical Technologies (SMT) announced significant new findings from four landmark clinical studies, namely TUXEDO II, Multivessel TALENT, Cruz Senior Study, and the SFlex Netherlands Registry, presented at the TCT 2025 conference. The collective data reinforces the proven safety, efficacy, and consistent performance of the Supraflex Cruz drug eluting stent (DES) across a broad spectrum of complex patient populations.